Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma

Learn more about:
Related Clinical Trial
The Impact of Mitotane Therapy on Serum Free Proteins in Patients With Adrenocortical Carcinoma Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma Natural History Study of Children and Adults With Adrenocortical Cancer (ACC) Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor International Pediatric Adrenocortical Tumor Registry Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer Structured Evaluation of adRENal Tumors Discovered Incidentally – Prospectively Investigating the Testing Yield Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients Efficacy of Adjuvant Mitotane Treatment (ADIUVO) Possible New Therapy for Advanced Cancer IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery Studying Genes in Samples From Younger Patients With Adrenocortical Tumor Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery Evaluation of Side Effects of Mitotane Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC) Surgery and Heated Chemotherapy for Adrenocortical Carcinoma Sunitinib in Refractory Adrenocortical Carcinoma Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInoma A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma Cabozantinib in Advanced Adrenocortical Carcinoma Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma German Adrenocortical Carcinoma Registry Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma

Brief Title

Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma

Official Title

Phase II Clinical Trial of Dovitinib (TKI-258) in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma

Brief Summary

      -  Design: non-randomized, open label, phase II clinical trial.

        -  Study population and disease: adult patients with metastatic or locally advanced
           non-resectable adrenocortical carcinoma, confirmed histologically.

        -  Estimated number of patients: 15.

        -  Study drug: dovitinib (TKI-258), dosed on a flat scale of 500mg/day on a 5 days on / 2
           days off.

        -  Treatment duration: study treatment period will be continued until disease progression,
           unacceptable toxicity, death or premature withdrawal from study. An average of 6 months
           treatment period is expected.

        -  Study duration: expected recruitment period will be 18 months, and patients will be
           followed for 6 additional months after last patient is included in the trial.Study total
           expected duration is 24 months.

        -  Sites: the study is planned to be conducted in 7 Spanish centers.

Detailed Description

      Non applicable

Study Phase

Phase 2

Study Type


Primary Outcome


Secondary Outcome

 Safety profile of dovitinib in study population


Adrenocortical Carcinoma



Study Arms / Comparison Groups

Description:  Dovitinib (TKI-258) f 500 mg / day (5 x 100mg) once daily. The patient will continue on treatment until disease progression,unacceptable toxicity, death or premature withdrawal.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

January 2012

Completion Date

November 2016

Primary Completion Date

July 2013

Eligibility Criteria

        Inclusion Criteria:

          -  Male or female patients aged ≥ 18 years old

          -  A performance status of 0, 1, or 2, according to the Eastern Cooperative Oncology
             Group (ECOG) scale.

          -  Histologically confirmed adrenocortical carcinoma.

          -  Metastatic or locally advanced non-resectable disease.

          -  At least one radiologically measurable lesion, according to RECIST 1.1.

          -  Adequate liver function as shown by: serum or plasma ALT and AST ≤ 3.0 x ULN
             (regardless of the presence or absence of metastases)and serum or plasma total
             bilirubin: ≤ 1.5 x ULN.

          -  Adequate bone marrow function as shown by: blood absolute neutrophil count (ANC) ≥ 1.5
             x 109/L, platelets ≥ 100 x 109/L and hemoglobin (Hb) > 9g/dL.

          -  Adequate renal function as shown by serum creatinine ≤ 1.5 x ULN.

          -  Patients give a written informed consent obtained according to local guidelines.

        Exclusion Criteria:

          -  Prior chemotherapy other than mitotane (Patients who have previously received mitotane
             will only be eligible if drig has been withdrawn at least two weeks earlier than
             dovitinib first dose is administered).

          -  Patients with another primary malignancy within 3 years prior to starting the study
             drug, with the exception of adequately treated in-situ carcinoma of the uterine
             cervix, or completely excised basal or squamous cell carcinoma of the skin.

          -  Patients who have received radical radiotherapy ≤4 weeks prior to starting the study
             treatment or who have not recovered from radiotherapy-related toxicities. Palliative
             radiotherapy for bone lesions ≤2 weeks prior to starting study treatment is allowed.

          -  Patients who have undergone any major surgery (i.e., intra-thoracic, intrabdominal, or
             intra-pelvic) ≤4 weeks prior to starting study treatment or who have not recovered
             from side effects of such therapy.

          -  Patients with a history of pulmonary embolism (PE) within the past 6 months or
             untreated deep-venous-thrombosis (DVT) within the past 6 months. Adequately treated
             DVT will be permitted providing that patient has been on anticoagulation for at least
             2 weeks.

          -  Patients with impaired cardiac function or clinically significant cardiac diseases,
             including any of the following:

               -  History or presence of serious uncontrolled ventricular arrhythmias.

               -  Clinically significant resting bradycardia.

               -  LVEF <45% when assessed by 2-D echocardiogram (ECHO) or multiple gated
                  acquisition scan (MUGA). (No basal cardiac test is mandatory other than ECG)

               -  Any of the following within 6 months prior to starting study treatment:
                  Myocardial infarction (MI), severe/unstable angina, Coronary Artery Bypass Graft
                  (CABG), Congestive Heart Failure (CHF),Cerebrovascular Accident (CVA), Transient
                  Ischemic Attack TIA).

               -  Uncontrolled hypertension defined by a SBP ≥160 mm Hg and/or DBP ≥100 mm Hg, with
                  or without anti-hypertensive medication. Initiation or adjustment of
                  antihypertensive medication (s) is allowed prior to study entry.

          -  Patients with impairment of gastrointestinal (GI) function or GI disease that may
             significantly alter the absorption of Dovitinib (TKI258) (i.e., severe ulcerative
             diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or
             extensive (>1m) small bowel resection, inability to swallow oral medications). Prior
             partial or total gastrectomy is not an exclusion criterion.

          -  Known diagnosis of human immunodeficiency virus (HIV) infection. HIV testing is not

          -  Patients who are currently receiving full dose of anticoagulation treatment with
             therapeutic doses of dicumarinical drugs as warfarin/acenocoumarol or anti-platelet
             therapy (i.e.,clopidogrel bisulfate). Treatment with acetylsalicyclic acid 100mg daily
             is allowed, as well as prophylactic or therapeutic low-weight-heparin.

          -  Pregnant or breast-feeding women.

          -  Women of child-bearing potential not employing an effective method of birth control.
             Effective contraception (e.g. condom with spermicidal jelly, foam suppository or film;
             diaphragm with spermicide; male condom and diaphragm with spermicide) must be used
             throughout the trial and 8 weeks after the end of Dovitinib treatment. Oral,
             implantable, or injectable contraceptives may be affected by cytochrome P450
             interactions, and are therefore not considered effective for this study. Women of
             child-bearing potential defined as sexually mature women who have not undergone a
             hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive
             months (i.e., who has had menses any time in the preceding 12 consecutive months),
             must have a negative serum pregnancy test ≤ 14 days prior to starting study drug.
             Women of child-bearing potential not employing and not willing to use an effective
             method of birth control. Post-menopausal women must have been amenorrheic for at least
             12 months to be considered of non-childbearing potential.

          -  Fertile males not willing to use contraception as stated above.

          -  Patients unwilling or unable to comply with the protocol.




18 Years - N/A

Accepts Healthy Volunteers



Jesús García-Donás Jiménez, MD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Secondary IDs


Responsible Party


Study Sponsor

Spanish Oncology Genito-Urinary Group

Study Sponsor

Jesús García-Donás Jiménez, MD, Principal Investigator, Spanish Oncology Genito-Urinary Group

Verification Date

April 2016